FDA Approves Camcevi ETM, a 3-Month Formulation of Leuprolide Mesylate for Advanced Prostate Cancer

The FDA approved leuprolide mesylate 21 mg, a long-acting injectable formulation administered every three months ...

AUGUST 29, 2025